We revised his underlying diagnosis from cryopyrin-associated periodic syndrome to early-onset sarcoidosis with wild-type <i>NOD2</i> and established a rationale to use the interleukin-6 (IL-6) receptor blocker tocilizumab (TCZ). This evidence concerns the gene IL6 and sarcoidosis.